Search for Clinical Trial Results

Sponsored By

Marginal Zone Lymphoma - 25 Studies Found

Status Study
Completed Study Name: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Condition: Marginal Zone Lymphoma
Date: 2007-03-27
Interventions:
  • Drug: Rituximab IV Infusion of
Active, not recruiting Study Name: Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma
Condition: Non-gastric Marginal Zone Lymphoma
Date: 2006-09-14
Interventions: Radiation: Involved Field Radiotherapy The prescribed dose
Not yet recruiting Study Name: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Condition:
  • Relapsed Marginal Zone Lymphoma
  • Refractory Marginal Zone Lymphoma of Ocular Adnexal
    Date: 2013-03-26
    Interventions: Drug: Doxycycline All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for f
Terminated Study Name: Gemcitabine for Marginal Zone Lymphoma
Condition:
  • Non-Hodgkin's Lymphoma
  • Marginal Zone Lymphoma

Date: 2006-06-14
Interventions: Drug: gemcitabine D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
Active, not recruiting Study Name: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Condition:
  • Marginal Zone Lymphoma
  • B-cell Lymphoma

Date: 2013-10-29
Interventions: Drug: ibrutinib
Terminated Study Name: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Condition:
  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Date: 2010-02-11
Interventions:
  • Drug: azacitidine Azacitidine

Active, not recruiting Study Name: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Condition: Marginal Zone B-cell Lymphoma
Date: 2016-07-26
Interventions: Drug: Bendamustine and Rituximab
Completed Study Name: Endomicroscopy and Gastric MALT-lymphoma
Condition: MALT-lymphoma
Date: 2012-01-08
Interventions:
  • Procedure: Confocal laser endomicroscopy

Recruiting Study Name: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Condition: Marginal Zone B-cell Lymphoma
Date: 2015-04-05
Interventions: Drug: bendamustine plus rituximab Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2
Next >>>